Claims for Patent: 10,047,163

Summary for Patent: 10,047,163

Title:	Multispecific constructs
Abstract:	Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
Inventor(s):	Liu; David (San Francisco, CA)
Assignee:	AbbVie Stemcentrx LLC (North Chicago, IL)
Application Number:	14/765,861
Patent Claims:	1. A bispecific bivalent antibody comprising a first binding region having a first CL domain comprising a S176K and N137K or N137R mutation, and a first CH1 domain comprising a S188D and T192D mutation; and a second binding region having a second CL domain comprising a S176D and N137D mutation and a second CH1 domain comprising a S188K and T192K mutation wherein the residues are numbered according to Kabat. 2. The bispecific bivalent antibody of claim 1 wherein said antibody further comprises a cytotoxic agent. 3. The bispecific bivalent antibody of claim 1 comprising a first binding region and a second binding region wherein said first and second binding region each comprise a light chain variable region and a heavy chain variable region from an antibody selected from the group consisting of abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, and CC49, wherein the first and second binding regions are from different antibodies.

Details for Patent 10,047,163

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-02-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-02-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-02-08
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2033-02-08